Suppr超能文献

过氧化物酶体增殖物激活受体γ配体和C/EBPβ增强子对细胞外超氧化物歧化酶表达的影响。

Effects of PPARgamma ligands and C/EBPbeta enhancer on expression of extracellular-superoxide dismutase.

作者信息

Adachi Tetsuo, Inoue Minoru, Hara Hirokazu, Suzuki Seiji

机构信息

Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan.

出版信息

Redox Rep. 2004;9(4):207-12. doi: 10.1179/135100004225005985.

Abstract

Extracellular-superoxide dismutase (EC-SOD) is the major SOD isozyme in the blood vessel walls and may be important for antioxidant capability of the vascular walls. Expression of EC-SOD is known to be regulated by numerous substances such as cytokines and vasoactive factors. Recently, we found that the plasma EC-SOD levels in type 2 diabetic patients were significantly and inversely related to indices of insulin resistance, whereas they were strongly and positively related to adiponectin. Administration of pioglitazone significantly increased the plasma level of EC-SOD and adiponectin. Transcription factors such as CCAAT/enhancer-binding proteins (C/EBPs) and peroxisome proliferator-activated receptors (PPARs) are known to regulate genes associated with insulin resistance. The aim of this study was to assess the contribution of these transcription factors on the EC-SOD level. We found that a C/EBPbeta enhancer, prolactin, significantly induced the EC-SOD mRNA and protein levels in cultured fibroblast cell lines, but PPARgamma ligands, pioglitazone and other thiazolidinedione agents did not. Deletion analysis of the EC-SOD promoter-luciferase construct showed that an important element responsible for prolactin is located between -242 and -178 in the promoter region of the EC-SOD gene in which a known C/EBPbeta-binding site is located. Increasing the EC-SOD expression by treatment with ligands of transcription factors might be one approach to ameliorate the pathological conditions of insulin resistance.

摘要

细胞外超氧化物歧化酶(EC-SOD)是血管壁中的主要超氧化物歧化酶同工酶,可能对血管壁的抗氧化能力很重要。已知EC-SOD的表达受多种物质调节,如细胞因子和血管活性因子。最近,我们发现2型糖尿病患者的血浆EC-SOD水平与胰岛素抵抗指标显著负相关,而与脂联素呈强正相关。吡格列酮治疗显著提高了血浆EC-SOD和脂联素水平。已知CCAAT/增强子结合蛋白(C/EBPs)和过氧化物酶体增殖物激活受体(PPARs)等转录因子可调节与胰岛素抵抗相关的基因。本研究的目的是评估这些转录因子对EC-SOD水平的影响。我们发现C/EBPβ增强子催乳素显著诱导培养的成纤维细胞系中EC-SOD的mRNA和蛋白水平,但PPARγ配体吡格列酮和其他噻唑烷二酮类药物则无此作用。对EC-SOD启动子-荧光素酶构建体的缺失分析表明,催乳素的一个重要元件位于EC-SOD基因启动子区域的-242至-178之间,该区域存在一个已知的C/EBPβ结合位点。通过转录因子配体治疗增加EC-SOD表达可能是改善胰岛素抵抗病理状况的一种方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验